DOI QR코드

DOI QR Code

Gallbladder Cancer: a Subtype of Biliary Tract Cancer Which is a Current Challenge in China

  • Qu, Kai (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Liu, Si-Nan (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Chang, Hu-Lin (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Liu, Chang (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Xu, Xin-Sen (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Wang, Rui-Tao (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Zhou, Lei (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Tian, Feng (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Wei, Ji-Chao (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Tai, Ming-Hui (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Meng, Fan-Di (Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University)
  • Published : 2012.04.30

Abstract

Biliary tract cancers, broadly described as malignancies that arise from the biliary tract epithelia, are usually divided into two major clinical phenotypes: cholangiocarcinoma and gallbladder cancer, differing in etiopathogenesis, risk factors, and perhaps molecular and genetic signatures. Atypical symptoms and lack of tumor biomarkers make it difficult to diagnose in early stages. At the time of presentation, few patients are candidates for potentially curative surgical resection. We here assessed and compared features of a total of 150 cases divided into extra- and intrahepatic cholangiocarcinomas and gallbladder cancers (GBC). Althought there were no significant differences in serum tumour marker levels, GBC patients had the poorest prognosis. Furthermore, gallbladder cancer respond poorly to chemotherapy or radiation therapy and approximately half of untreated patients died within 10 months. Therefore, treatment for patients with gallbladder cancer is still in challenge. Outcomes and survival of these patients had improved little over the past three decades - a period in which new successful treatments have greatly contributed to the prolonged patient survival for many other cancers.

Keywords

References

  1. Aljiffry M, Walsh MJ, Molinari M (2009). Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol, 15, 4240-62. https://doi.org/10.3748/wjg.15.4240
  2. Bartlett DL, Fong Y, Fortner JG, et al (1996). Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg, 224, 639-46. https://doi.org/10.1097/00000658-199611000-00008
  3. Dixon E, Vollmer CM Jr, Sahajpal A, et al (2005). An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg, 241, 385-94. https://doi.org/10.1097/01.sla.0000154118.07704.ef
  4. Hueman MT, Vollmer CM Jr, Pawlik TM (2009). Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol, 16, 2101-15. https://doi.org/10.1245/s10434-009-0538-x
  5. Lazcano-Ponce EC, Miquel JF, Munoz N, et al (2001). Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin, 51, 349-64. https://doi.org/10.3322/canjclin.51.6.349
  6. Onori P, Gaudio E, Franchitto A, et al (2010). Histamine regulation of hyperplastic and neoplastic cell growth in cholangiocytes. World J Gastrointest Pathophysiol, 1, 38-49.
  7. Patel T (2002). Worldwide trends in mortality from biliary tract malignancies. BMC Cancer, 2, 10. https://doi.org/10.1186/1471-2407-2-10
  8. de Groen PC, Gores GJ, LaRusso NF, et al (1999). Biliary tract cancers. N Engl J Med, 341, 1368-78. https://doi.org/10.1056/NEJM199910283411807
  9. Patel T (2004). Worldwide trends in mortality from biliary tract malignancies. BMC Cancer, 2, 10.
  10. Rajagopalan H, Lengauer C (2004). Aneuploidy and cancer. Nature, 432, 338-41. https://doi.org/10.1038/nature03099
  11. Randi G, Franceschi S, La Vecchia C (2006). Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer, 118, 1591-602. https://doi.org/10.1002/ijc.21683
  12. Shrikhande SV, Barreto SG, Singh S, et al (2010). Cholelithiasis in gallbladder cancer: coincidence, cofactor, or cause! Eur J Surg Oncol, 36, 514-9.
  13. Song SC, Heo JS, Choi DW, et al (2011). Survival benefits of surgical resection in recurrent cholangiocarcinoma. J Korean Surg Soc, 81, 187-94. https://doi.org/10.4174/jkss.2011.81.3.187
  14. Welzel TM, McGlynn KA, Hsing AW, et al (2006). Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst, 98, 873-5. https://doi.org/10.1093/jnci/djj234
  15. Wistuba II, Gazdar AF (2004). Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer, 4, 695-706. https://doi.org/10.1038/nrc1429
  16. Wolpin BM, Mayer RJ (2010). A step forward in the treatment of advanced biliary tract cancer. N Engl J Med, 362, 1335-7.

Cited by

  1. Platelet Derived Growth Factor-B and Human Epidermal Growth Factor Receptor-2 Polymorphisms in Gall Bladder Cancer vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5647
  2. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3451
  3. Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin vol.19, pp.1, 2019, https://doi.org/10.1186/s12885-018-5211-y